ZEUS System vs LINQ II Insertable Cardiac Monitor
AI Verdict
Choose ZEUS System if…
Choose ZEUS System if you require a non-invasive, AI-powered solution for continuous cardiac monitoring over a period of up to 14 days, utilizing wearable biosensors. This tool is ideal for initial diagnostic assessments of symptomatic or asymptomatic arrhythmias, offering cloud-based data analytics and preliminary report generation to streamline physician workflow.
View ZEUS System →Choose LINQ II Insertable Cardiac Monitor if…
Choose LINQ II Insertable Cardiac Monitor if your patient requires discreet, ultra-long-term continuous heart rhythm monitoring for up to 4.5 years, particularly for detecting infrequent arrhythmias or in cases of cryptogenic stroke. This insertable device offers enhanced AI-powered accuracy, remote programming capabilities, and MRI compatibility, making it suitable for patients needing extended surveillance where wearable options are insufficient.
View LINQ II Insertable Cardiac Monitor →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | ZEUS System | LINQ II Insertable Cardiac Monitor |
|---|---|---|
| Pricing | Not disclosed | Unknown |
| Deployment | Cloud-based (AWS EC2 platform), no on-premise hardware. | Subcutaneous implant with remote monitoring via mobile app or home communicator. |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
ZEUS SystemTool A offers a non-invasive patient experience through wearable sensors, coupled with cloud-based data analytics and HL7-based EHR integration for streamlined physician workflow. While Tool B provides remote programming and patient apps, the initial invasive procedure for implantation makes it less 'usable' from a holistic patient perspective compared to Tool A's approach.
Clinical Value
LINQ II Insertable Cardiac MonitorTool B provides significantly longer continuous monitoring, up to 4.5 years, which is crucial for detecting infrequent or asymptomatic arrhythmias over extended periods, compared to Tool A's 14-day monitoring. Its advanced AccuRhythm AI algorithms, innovative PVC detection, and pediatric indication further enhance its diagnostic capabilities and clinical applicability.
Pricing & Value
TieBoth tools lack transparent, publicly disclosed pricing information, making a direct comparison of their cost-effectiveness and overall value proposition impossible. Without specific pricing models or publicly available data, it is not feasible to definitively determine which offers better value.
Enterprise Readiness
LINQ II Insertable Cardiac MonitorTool B, backed by Medtronic's extensive history (founded 1949) and global presence, has been deployed in over 1 million patients worldwide and explicitly targets a wide range of healthcare systems from solo practices to large health systems. This demonstrates a robust and proven infrastructure for enterprise-level adoption and support.
Innovation
LINQ II Insertable Cardiac MonitorTool B demonstrates greater innovation through its long-term implantable monitoring capabilities (up to 4.5 years), remote programming, and specialized AI algorithms like AccuRhythm and innovative PVC detection. Its pediatric indication and MRI compatibility also expand its utility and represent advanced features in cardiac monitoring technology.
Support & Docs
LINQ II Insertable Cardiac MonitorWhile explicit details on 'Support & Docs' are limited for both, Tool B provides specific patient-facing support tools such as the MyCareLink Heart mobile app and MyCareLink Relay home communicator for data transmission. Furthermore, Medtronic's status as a large, established global medical device company strongly implies comprehensive and robust support infrastructure and documentation for both clinicians and patients.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | ZEUS System | LINQ II Insertable Cardiac Monitor |
|---|---|---|
| Monitoring Method | Analyzes ECG data from wearable biosensors for continuous cardiac monitoring. | Insertable cardiac monitor for continuous heart rhythm monitoring. |
| Company | iRhythm Technologies | Medtronic |
| Tagline | AI-powered cardiac monitoring for early arrhythmia detection and management. | Advanced insertable cardiac monitoring with AI-powered accuracy and remote management. |
| Maximum Monitoring Duration | Up to 14 days | Up to 4.5 years |
| Key AI Feature | AI-powered arrhythmia detection, detection and characterization of Atrial Fibrillation (AFib). | AccuRhythmu2122 AI algorithms for enhanced accuracy, innovative PVC detection algorithm. |
| Patient Data Transmission | Integration with Zio Watch and Zio monitors; HL7-based EHR integration. | MyCareLink Heartu2122 mobile app for data transmission, MyCareLink Relayu2122 home communicator option. |
Videos
Demos, reviews, and walkthroughs featuring ZEUS System and LINQ II Insertable Cardiac Monitor.
Frequently Asked Questions
More Comparisons
More matchups featuring ZEUS System or LINQ II Insertable Cardiac Monitor
Backers
Who funded each tool's parent company.